Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world multicenter study of mecapegfilgrastim for prevention of chemotherapy-related neutropenia
ChiCTR2000031768Phase 4Recruiting
- Sponsor
- Institute of Hematology and Oncology, Harbin First Hospital
- Start
- May 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of mecapegfilgrastim in chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN), sponsored by Institute of Hematology and Oncology, Harbin First Hospital. Primary endpoint: Safety. Started May 2019; status: recruiting.
02
Drugs
mecapegfilgrastim
03
Conditions
chemotherapy-induced neutropenia (CIN)febrile neutropenia (FN)
Beyond the preview
Go deeper on ChiCTR2000031768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000031768.